Background -Epidemiological data suggests that gender independently contributes to
Introduction
Gender has been observed to contribute independently to cardiovascular risk but the underlying mechanisms are poorly understood. Epidemiological data from the Framingham Study show later onset and lower prevalence of cardiovascular disease in females 1 . In addition, results from 37 WHO MONICA (Monitoring of trends and determinants in Cardiovascular diseases) project populations, and cardiovascular mortality data within Europe demonstrate lower rates of coronary heart disease mortality in females than in males 2, 3 . Data regarding gender-related outcomes based on controlled clinical studies with contemporary drug treatments are sparse, mainly due to un-equal proportions of male and female patients being enrolled in large-scale cardiovascular clinical outcome trials.
ONTARGET (25,620) 4 and TRANSCEND (5,926 patients) 5 recruited > 30,000 patients, aged 55 years with high-risk cardiovascular disease, or diabetics with signs of end-organ damage. These patients -the largest study group of cardiovascular high-risk patients so farwere on guideline recommended protective treatments. We hypothesized that gender independently impacts on cardiovascular risk in this cohort. Clinical trials, in particular in cardiovascular fields, generally face the difficulty of very high proportions of male patients.
ONTARGET had recruited 26.7% and TRANSCEND 43.0% females. Thus, this high percentage of female patients allowed us to aim at analyses of the primary and secondary composite outcomes in male vs. female patients (irrespective of pharmacological intervention) in order examine drug-independent gender-specific outcomes.
Subjects, materials and methods

Study population
The design of the ONTARGET and TRANSCEND trials, including patient eligibility criteria, cardiovascular clinical outcome trials.
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Intolerance was defined as previous ACE-inhibitor discontinuation by a physician for intolerance with a specific documented cause. The studies were performed in 733 and 630 centers respectively for ONTARGET and TRANSCEND, in 40 countries. After randomization patients were followed up at 6 weeks, 6 months and afterwards every 6 months. The study protocol was approved by the Research Ethics Board of each participating center. All subjects provided written informed consent. The study was performed according to Good Clinical Practice (GCP) / US Food and Drug Administration (FDA) rules with rigorous monitoring and adjudication of all endpoints.
Measures
N=25,620 patients and n=5,926 patients underwent randomization in ONTARGET and TRANSCEND, respectively. Baseline characteristics were obtained by clinical assessment. The primary outcome was the composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, or hospitalization for heart failure (CHF). Secondary outcomes were the composite outcome of CV death, MI, or stroke (which was the primary outcome of the HOPE trial) 7 . Other secondary outcomes included separate counts of non-fatal MI, stroke, and hospitalization for CHF. Of initially 31,546 patients enrolled, 5,730 (18.2%) stopped study medication by the fourth year.
Statistical analyses
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N=25,620 p pat at tie ie ient nt n s s s an an a d d d n= n n 5, 5, 5,92 92 926 6 6 pa pa p ti ti ien en e ts ts ts u u und nd nder er erw w wen en ent t t ra ra r nd nd dom om omiz iz izat at atio io ion in in in O O ONT NT NTAR AR ARGE GE GET T T an an a d years. These cut-offs represent well the age range of patients in the two studies who were all at least 55 years. In contrast to inclusion of age as a continuous variable, the categorical approach does not require that the relationship between risk and age is linear and leaves more flexibility in modeling the data. However, for the estimation of the average time delay of events in females compared to males, age was included as a continuous variable. In this model the time delay can be calculated as the ratio of the coefficients for gender and age on the log-scale. This value is equivalent to the time span in years a female patient has to be older to have the same hazard as a male patient with otherwise identical risk factors; approximate confidence intervals were calculated using the delta method.
The association between gender and age as well as between gender and other risk factors was explored using the Cox model including the respective risk factor and interaction with gender. We also explored potential gender differences in patients with an MI and/or stroke during the trial. In these patients we compared the event rates of CV death, further MI or stroke or subsequent hospitalization for CHF using the same methodology as described above.
Statistical analyses were done with SAS, version 9.2. The studies were registered as NCT00153101 at ClinicalTrials.gov.
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Results
Baseline characteristics of male vs. female patients
These are shown in Table 1 . Female patients were older and were characterized by less physical activity. Males had a higher prevalence of current or formerly tobacco use and a higher prevalence of alcohol consumption. While coronary artery disease was more frequent in males than in females, females exhibited a higher prevalence of previous stroke, high-risk diabetes, and hypertension.
Outcome in male vs. female patients
The annualized rates of the primary outcome, the 3-fold endpoint (as for HOPE), and single endpoints are shown in Table 2 .
After adjustment for age, ethnicity, BMI, physical activity, formal education, smoking, alcohol drinking, prior MI, prior stroke, history of hypertension, diabetes, clinical diagnosis at study entry, and concomitant medication at baseline females had a 19% lower risk for the 4-fold endpoint ( Table 2 and Figure 1A ), a 21% lower risk for the 3-fold endpoint ( Table 2 and Figure 1B) , and a 22% lower risk for MI in (Table 2 and Figure 1C ). In addition, for CV death there was also a significantly lower risk in females than males by 17%. In contrast the risks for both stroke and hospitalization for CHF were not different ( Table 2) . As also depicted in Figures 1A, 1B, and 1C , further sub-analyses of the 4-fold-, 3-fold-, and MI-outcome with regard to gender and age are shown in Supplemental Table 1. While the overall incidence for all endpoints was significantly lower in females, the gender difference was consistent across age groups with no indication of any gender-by-age-interaction (Supplemental Table 1 ). Overall, from the confounders included in the model, age, diabetes, history of MI or stroke, physical activity and smoking (depending on the actual endpoint) exhibited the biggest predictive value. endpoints are shown in Table 2 .
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Also, in patients with previous MI, women had a lower risk than males throughout all age groups ( Figure 1D ).
Time delay of events in female compared to male patients
The difference in the risk of CV events between females and males can be quantified in terms of the average time delay of a specific event for a female patient compared to a male patient with the same risk profile, i.e. otherwise identical confounders. The calculated delay for the combined 4-fold endpoint was 5.7 years, and for the 3-fold endpoint 6.3 years. Among the analyzed endpoints the time delay for experiencing an MI was greatest with 10.7 years (Supplemental Table 2 ).
Gender-differences in risk factor associations with acute MI
Sub-analyses were performed for risk factor associations with incidence of acute MI (Figure 2) . Hypertension, previous MI, stroke, current or formerly smoking, and physical activity did not differently impact on the incidence of acute MI between females and males (no indication for interaction between gender and risk factor). In contrast, diabetes and alcohol consumption affected outcome of MI between males and females differently. In diabetic patients, females were at higher risk for an acute MI. Conversely, while alcohol consumption was associated with reduced risk for MI in both genders, this reduction was significantly greater in females ( Figure   2 ).
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Tracking events after an MI or after a stroke
Further analyses were performed to clarify whether an acute MI and/or a stroke predicts the risk for subsequent events. As shown in Table 4 , patients experiencing an MI during the course of the studies had higher rates for a second MI than for a stroke but, nevertheless, a substantial portion of male and female patients with a previous MI had a subsequent stroke (annualized rates of 1.60% and 2.38%, respectively). Conversely, patients with a stroke had higher rates for a subsequent stroke, but also a substantial number of MI (annualized rates of 1.90% for males and 1.92% for females). However, after full adjustment for all potential confounders, there were no gender-specific differences regarding the annualized rates between patients with primary MI.
While CV death occurred at comparable rates in patients with MI or stroke, the incidence for CHF hospitalization was clearly higher in both female and male patients with MI than in those with stroke (Table 4) . Overall, the high rates of 17-25% annualized rates for the composite endpoint in either patient group (previous MI or stroke) demonstrate the general interdependence of cardiovascular endpoints.
Cardioprotective treatment
Differences in clinical diagnosis and patient history at study entry were reflected by differences in medication ( Table 5) . Female patients were treated more frequently with anti-hypertensives and anti-diabetics, while statins/fibrates and anti-coagulants were more frequently prescribed in males. In addition, the number of co-medications including anti-hypertensives, anti-coagulants, anti-diabetics, and statins/fibrates significantly differed between males and females both at study entry, and at final visit with or without the occurrence of a primary event. The occurrence of the primary event led to higher proportions of both female and male patients receiving the number of four concomitant medications ( Table 5) . With the exception of anti-coagulants in males, While CV death occurred at comparable rates in patients with MI or stroke, the in in nci ci ide denc n nce e e fo fo for r CHF hospitalization was clearly higher in both female and male patients with MI than in those wi with th h s s str tr trok ok oke e e ( ( (T T Tabl bl ble e e 4 4). Overall, the high rates of f 1 17 1 ---25% annualize ze ed ra ate te tes s s for the composite en nd dp dpoint in ei ith th he e er p pat atie ie i nt nt nt g g gro ro roup u up ( (p p pre re evi viou ou us M M MI or s st tr ro oke e e) ) ) de demo mo mons nst tra at ate e th th the ge gene ne nera ral l in in inte te terd rd rdep p pen ende de d n nc n e of f f c c car ar rdi di d ov ovas as asc cu cula lar r e en endp dp dpo oi int nts.
Cardioprotec ec cti ti tive ve e t t tre re r at at atme me ent nt nt by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from compared to the situation at study entry medications were more frequently given at the final visit in those experiencing the primary event, particularly anti-diabetics and statins/fibrates.
Discussion
In this post-hoc analysis we investigated differences in cardiovascular outcome related to gender, based on a non-epidemiological controlled study cohort of > 30,000 high-risk patients on optimal standard treatment.
We observed a better outcome in female than in male patients which was robust after adjustment for various confounders (age, ethnicity, BMI, physical activity, formal education, smoking, alcohol drinking, prior MI, prior stroke, history of hypertension, history of diabetes, and concomitant medication at baseline). There were significantly lower risks in female patients for the 4-fold endpoint, the 3-fold endpoint and for MI by 19%, 21%, and 22%, respectively, which is also directly evident by significantly lower annualized incidence rates in females. Our data further indicate that female patients develop cardiovascular endpoints approximately 5-10 years later than males with smaller differences at later ages. Male patients recruited at later ages might be likely to be at lower risk compared to earlier ages, because of attrition of higher risk males.
At study entry the number of co-medications significantly differed between males and females. This does not necessarily represent under-treatment in females, since the type of medications reflected the patient history and disease at the time of enrollment. In particular, the higher prevalence of hypertension and diabetes in females was reflected by a higher percentage of drug treatment with anti-hypertensives and anti-diabetics. In contrast, male patients had significantly higher prevalence of myocardial infarction in their history, which likely resulted in moking, alcohol drinking, prior MI, prior stroke, history of hypertension, histor ry y y of of o d d dia ia iabe be bete te tes, s, and concomitant medication at baseline). There were significantly lower risks in female patients fo or r th th the e e 4 4-4-fo fo fold ld ld end nd dp po point, the 3-fold endpoint and fo fo for r MI by 19%, 2 21% 1 1 , , an an and d 22%, respectively, w whi ic ich is also di di ire rec c ctly y e evi vi vide de dent nt nt b b by y si si sig gn gni if fic c cantl tl ly low we wer r an n nn nu nual al liz zed ed i in nc cid iden en nc ce e r ra at ate es es i in n n fe fe fema ma ale e es s. O O Ou u ur da data ta ta f f fur ur u th ther er r i i ind ndic ic cat at te e th th hat at t f fem em ma ale le e p p pat at ati ie ien nt nts s de de dev ve velo lo lop p p ca ca ard rdio iova va vas sc scu u ula la lar r en en ndp dp d o o oin nt nts s ap ap appr pr prox ox xim im mat at tel ly y y 5-5--10 0 0 years later th han an an m m mal al ales es e w w with h h sm sm mal al lle le ler r di di d ff ff fer er e en en ence ce ces s s at at at l lat at ater er e a a age ge ges. s s M M Mal al ale e pa pa pati ti tien en ents ts ts r r rec ecru ru ruit it ited ed ed a a at t later ages significantly more male patients being treated with statins/fibrates and anti-coagulants at study entry. The clinical outcome of patients during the trials largely impacted on the given medications. The occurrence of the primary event was followed by higher frequencies of antihypertensives, anti-diabetics, and statins/fibrates in both male and female patients.
Irrespective of gender, age contributes significantly to cardiovascular risk. Thus, in both male and female patients, higher age was associated with increased risk for the 4-fold endpoint, the 3-fold endpoint, and the individual secondary outcomes of cardiovascular death, MI, stroke, and hospitalization for heart failure. Cardiovascular endpoints occurred approximately 5 years later in females while myocardial infarction displayed an approximately 10 year delay. Thus, the beneficial outcome in females -after adjustment for various factors -was largest for MI. The reason for the female-related benefit in particular with regard to MI, but less for stroke, remains unclear, but is in line with previous reports in epidemiological investigations on Swedish and Finnish populations 8 . In contrast, hospitalization for chronic heart failure was -after adjustment -not different between males and females. The recent EuroHeart Failure Survey II also did not demonstrate gender-associated differences 9 . A pooled analysis of 5 randomized clinical trials on gender-related differences in aetiology and outcome (all-cause mortality and death or all-cause hospitalization) in patients with CHF likewise did not produce differences based on gender 9 .
While adjustment only for study (ONTARGET vs. TRANSCEND) and treatment only showed a higher incidence of CHF hospitalization in females, this gender-related difference disappeared after additional adjustment for age, BMI, physical activity, smoking, alcohol consumption, education, ethnicity, previous MI, previous stroke, hypertension, diabetes, clinical diagnosis at study enty, and concomitant medication at baseline. Sub-analyses of defined risk factorassociations revealed that hypertension, former MI, stroke, smoking and physical activity are not beneficial outcome in females -after adjustment for various factors -was largest st t f for o o M M MI. I. I T T The h he t eason for the female-related benefit in particular with regard to MI, but less for stroke, remains un ncl cl clea ea ar r, r, b b but ut ut i is s in n n l l li in ine with previous reports in ep p pi id ide e emiological inv nv ves e ti iga ga gat ti tions on Swedish and F Finn n nish popula lati ti tion on ons 8 8 8 . . In n n c c con on ontr tr tras ast, t h h hos os o p pi pit taliz z zat t tion fo o or c c chr hr ron oni ic c he hea ar art t t fa fail il ilur ure e wa wa was s --af af a te te er r ad ad a ju ju just st tme m ment -no no not t di di d ff ffer er ren en ent t be be etw w wee ee en n ma ma m le es s s an an nd d d fe fe fem ma male le es. s s. T T The he he re re ec ce ent t t E E Eur ur uroH oH oHea ea e r r rt However, the risk factors diabetes and alcohol consumption showed a gender-associated impact on incidence of acute MI. In agreement with the INTERHEART study 10 , a standardized case-control study of acute MI, diabetes was a stronger risk factor for MI in females compared to males. Morrish et al. 11 reported that incidence rates of macrovascular diseases were similar between diabetic men and women with the exception of MI in those patients with non-insulindependent diabetes, where male patients were characterized by a significantly higher incidence rate. While it is well acknowledged that diabetes, in general, markedly contributes to the risk of cardiovascular disease, this risk has previously been found greater in females than in males 12 .
This is in congruence with our recent data. However, Lundberg et al. 12 investigated diabetes as a risk factor for acute MI from a population perspective in a region with high cardiovascular disease risk and was based on a population-based acute MI register with a total of 2432 men and women aged 35-64 years. Thus, our study group significantly differs from this cohort by higher number of investigated patients, and a combined data set of two large-scale controlled studies with patients on optimal standard therapy for individual cardiometabolic diseases including diabetes. Moreover, as in the standardized case-control INTERHEART, we observed a significantly stronger impact of alcohol on reducing the risk for acute MI in females than in males. The underlying mechanism for this finding has not been established so far. While it is generally agreed that light to moderate alcohol consumption is inversely correlated with cardiovascular risk 13, 14 , our findings should not be used to promote alcohol consumption as a cardiovascular preventive strategy, since alcohol has also several other adverse health consequences such as cancer and injuries 15, 16 .
This is in congruence with our recent data. However, Lundberg et al. 12 
Limitations
Our data are non-randomised observations from two clinical trials albeit comprising more than 30,000 patients. While epidemiological analyses frequently cover periods of decades, our observation was limited to 5 years. An additional limitation is that in these two clinical trials only high-risk patients were enrolled.
Conclusions
With a total of n=31,546 patients (males: 70.3%; females: 29.7%), a median follow-up of 56 months, and after adjustment for potential confounders we report a ~20% lower risk for combined cardiovascular endpoints in female patients, which was mainly driven by significantly lower incidence of MI. Thus, we demonstrate that gender largely impacts on occurrence of cardiovascular events in patients with vascular disease or high-risk diabetes, and this occurs despite cardioprotective therapy. Previously, the time difference between males and females with regard to occurrence of a cardiovascular endpoint has been estimated between 5 to 10 years. This was true for the combined endpoints but not for myocardial infarction. Interestingly, despite their lower risk in the total population, diabetic women were at greater risk than diabetic man to develop MI. In contrast, hospitalisation for chronic heart failure was, after adjustment, not different between males and females in all age groups.
Taken together, our data clearly point out significant gender-related differences in cardiovascular outcome in patients with vascular disease or high risk diabetes. Despite appropriately individualized cardioprotective therapy, female patients are at lower net cardiovascular risk than males, and develop cardiovascular endpoints approximately 5-10 years later.
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